New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
05:32 EDTCTIC, BAXCTI BioPharma completes recruitment in PERSIST-1 Pacritinib Phase 3 trial
CTI BioPharma (CTIC) announced that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International (BAX), CTI expects to receive a $20M development milestone payment in connection with the first treatment dosing of the last patient enrolled in PERSIST-1. CTI expects to achieve this milestone and receive payment by mid-Q3.
News For CTIC;BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:02 EDTBAXBaxter presents IGSC 20% Phase 2,3 study
Subscribe for More Information
October 29, 2014
16:18 EDTCTICCTI BioPharma raises FY14 operating loss view to $66M-$71M from $45M-$50M
As a result of the stock issuance in the transaction described above with Chroma resulting in an expense recognition of approximately $21M, CTI has revised its financial guidance such that non-GAAP operating loss for 2014 is now expected to range from approximately $66M-$71M rather than $45M-$50M as previously expected, which excludes non-cash share-based compensation expense.
16:16 EDTCTICCTI BioPharma reports Q3 EPS 3c, consensus (3c)
Reports Q3 revenue $39.53M, consensus $24.3M.
October 27, 2014
07:23 EDTBAXAmerican College of Surgeons holds a conference
Subscribe for More Information
07:22 EDTBAXAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
05:14 EDTCTICCTI BioPharma acquires exclusive worldwide license to tosedostat
Subscribe for More Information
October 24, 2014
09:02 EDTBAXBaxter says FDA approves Obizur for acquired hemophilia A
Subscribe for More Information
October 21, 2014
06:29 EDTBAXBaxter management to meet with Leerink
Subscribe for More Information
October 20, 2014
09:04 EDTBAXBaxter, Halozyme launch HYQVIA in U.S.
Subscribe for More Information
October 16, 2014
09:04 EDTBAXBaxter says spin-off of BioScience division on track for mid-2015 completion
Subscribe for More Information
09:02 EDTBAXBaxter says it still has not experienced competition for cyclophosphamide
Subscribe for More Information
08:38 EDTBAXBaxter expects divestiture of vaccines business to Pfizer to close in Q4
Subscribe for More Information
07:03 EDTBAXBaxter sees FY14 continuing ops EPS $4.86-$4.89, consensus $5.16
Subscribe for More Information
07:02 EDTBAXBaxter sees Q4 continuing ops EPS $1.30-$1.33, consensus $1.41
Sees Q4 sales growth approx. 3% excluding the impact of foreign currency. Including the impact of foreign currency, the company expects reported sales to be flat to 2013 levels. Consensus is $4.39B.
07:01 EDTBAXBaxter reports Q3 adjusted EPS $1.35, consensus $1.31
Reports Q3 revenue $4.2B, consensus $4.2B.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use